Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 5—May 2023

Emergence of Erythromycin-Resistant Invasive Group A Streptococcus, West Virginia, USA, 2020–2021

Lillie M. Powell, Soo Jeon Choi, Chloe E. Chipman, Megan E. Grund, P. Rocco LaSala1, and Slawomir Lukomski1Comments to Author 
Author affiliation: West Virginia University, Morgantown, West Virginia, USA

Cite This Article


CME Logo


In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at; and (4) view/print certificate.

Release date: April 14, 2023; Expiration date: April 14, 2024
Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess the clinicoepidemiology of invasive group A Streptococcus pyogenes infections, based on a study of 76 invasive group A Streptococcus pyogenes isolates from 66 patients identified at J.W. Ruby Memorial Hospital in West Virginia from 2020 to 2021

  • Evaluate the specific phenotypic and genotypic antimicrobial resistance traits of available isolates from invasive group A Streptococcus pyogenes infections, based on a study at J.W. Ruby Memorial Hospital in West Virginia from 2020 to 2021

  • Determine the clinical and public health implications of the clinicoepidemiology of invasive group A Streptococcus pyogenes infections and specific phenotypic and genotypic antimicrobial resistance traits of corresponding available isolates, based on a study at J.W. Ruby Memorial Hospital in West Virginia from 2020 to 2021

CME Editor

Jill Russell, BA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Jill Russell, BA, has no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has no relevant financial relationships.


Lillie M. Powell, BS; Soo Jeon Choi, MS; Chloe E. Chipman; Megan E. Grund, BS; P. Rocco LaSala, MD; and Slawomir Lukomski, PhD.



Clindamycin and β-lactam antibiotics have been mainstays for treating invasive group A Streptococcus (iGAS) infection, yet such regimens might be limited for strains displaying MLSB phenotypes. We investigated 76 iGAS isolates from 66 patients in West Virginia, USA, during 2020–2021. We performed emm typing using Centers for Disease Control and Prevention guidelines and assessed resistance both genotypically and phenotypically. Median patient age was 42 (range 23–86) years. We found 76% of isolates were simultaneously resistant to erythromycin and clindamycin, including all emm92 and emm11 isolates. Macrolide resistance was conferred by the plasmid-borne ermT gene in all emm92 isolates and by chromosomally encoded ermA, ermB, and a single mefA in other emm types. Macrolide-resistant iGAS isolates were typically resistant to tetracycline and aminoglycosides. Vulnerability to infection was associated with socioeconomic status. Our results show a predominance of macrolide-resistant isolates and a shift in emm type distribution compared with historical reports.

Streptococcus pyogenes, also known as group A Streptococcus (GAS), is a ubiquitous pathogen that produces an array of human disease, including focal infections (e.g., pharyngitis, pyoderma) with or without localized suppurative complications; invasive soft tissue infections (e.g., myositis, necrotizing fasciitis); and systemic, often fatal, infections (e.g., bacteremia, toxic shock syndrome). In addition, 2 postinfectious complications (glomerulonephritis and rheumatic heart disease) attributable to GAS have been well described (13). Although GAS remains susceptible to penicillin, treatment with alternative or combination therapies, such as macrolides, clindamycin, and other second-line antimicrobial medications, is common because of patient β-lactam allergies, dosing convenience, infection severity, and patient acuity (4). In contrast to its predictable β-lactam susceptibility, GAS resistance to other classes of antimicrobial drugs has been increasingly reported (57). In the face of ongoing dissemination of the MLSB (macrolide, lincosamide, and streptogramin B) resistance phenotypes among GAS isolates, the Centers for Disease Control and Prevention (CDC) has labeled macrolide-resistant GAS an emerging threat of concern (8).

As 1 component of its Active Bacterial Core surveillance (ABCs) system, the CDC Emerging Infections Program, part of the National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, provides ongoing population-based assessments of GAS infections from 10 sites in the United States. Annual reports produced by the program estimate the incidence of invasive GAS (iGAS) infections within the United States doubled from 2009 to 2019; total numbers of infections increased from ≈11,000 cases (3.6 cases/100,000 population) to >25,000 cases (7.6 cases/100,000 population) (9,10). Concomitant with this change, substantial increases in the proportion of iGAS isolates resistant to erythromycin and clindamycin have been reported; overall resistance rates climbed from <10% in 2010 to near 25% by 2017 (11). Populations at risk for such macrolide-resistant iGAS infections have been predominantly persons 18–64 years of age; incidence is high among persons with a history of intravenous drug use (IVDU) and persons experiencing homelessness (11,12).

West Virginia, USA, has seen a noticeable increase in annual rates of iGAS erythromycin resistance; at West Virginia University Medicine System (WVUMed) hospitals in Morgantown, rates increased from 37% in 2019 to 54% in 2020 and 87% in 2021. The state also has an extremely high per capita rate of drug overdose (13). On the basis of all those considerations, we conducted a study to review clinicoepidemiology of iGAS infections within the region and to characterize specific phenotypic and genotypic antimicrobial resistance traits of corresponding available isolates.

Materials And Methods

Study Setting

The clinical laboratory at J.W. Ruby Memorial Hospital in Morgantown serves as the primary reference facility for all 19 WVUMed hospitals located throughout West Virginia, as well as facilities in western Maryland, southwestern Pennsylvania, and eastern Ohio. The WVUMed system serves an estimated patient population of 1.2 million. Most microbiological testing at J.W. Ruby Memorial Hospital and surrounding WVUMed outpatient clinics is performed by the Ruby clinical laboratory, as is referral antimicrobial susceptibility testing of many Streptococcus spp. isolates. The clinical laboratory routinely banks invasive isolates at −80C for 1–2 years. Noninvasive isolates, including those recovered from pharyngitis cases, are not routinely held >7 days after specimen submission.

The strain collection for this study included all viable primary and referred iGAS isolates available from the freezer bank, which spanned the period January 2020–June 2021. After approval by the hospital’s Institutional Review Board (protocol no. 2202533507), we reviewed patient records to capture demographic and clinical information, such as patient age, sex, residence status, history of IVDU, intensive care unit admission requirement, number of surgical interventions, antimicrobial regimen, and clinical outcome (Appendix Table 1), for all isolates successfully retrieved. We included 2–4 replicate isolates recovered serially from 8 patients and tested them separately as a quality control measure. In all instances, intrapatient phenotypic and genotypic results were consistent, so isolates are reported per patient throughout.

Chromosomal and Plasmid DNA Isolation

We isolated genomic DNA from a 10-μL loopful of bacteria grown in Todd Hewitt broth by using the DNA extraction procedure, as described previously (14). We isolated plasmid DNA by using Gene JET Plasmid Miniprep Kit (ThermoFisher Scientific) with an additional cell-digestion step (1 mg/mL lysozyme and 0.5 U/µL mutanolysin) at 37°C for 1 hour. We analyzed plasmid DNA, uncut and digested with SwaI, on a 0.8% agarose gel for confirmation of plasmid pRW35 size in emm92 isolates (15).

Identification of Resistance Genes erm/mef and emm Typing

We used plasmid DNA as a PCR template with the ermT-specific primers, whereas we used genomic DNA as the PCR template with primers detecting ermA(TR), ermB(AM), and mefA genes (Appendix Table 2). We obtained control GAS strains harboring the corresponding erm and mef genes from the CDC Streptococcus Laboratory ( We used genomic DNA to determine isolate emm type by Sanger sequencing of amplicons generated with primers emm1b and emm2 (16), followed by BLAST search ( on the CDC Streptococcus Laboratory.

Antimicrobial Susceptibility Testing

We performed erythromycin, clindamycin, and tetracycline susceptibility testing in the clinical microbiology laboratory by using methods described by the Clinical Laboratory Standards Institute (CLSI) (17). All automated testing used Vitek 2 ST-02 cards (bioMériuex) and was performed upon isolate recovery for clinical management purposes. All valid results were reported to and retrieved from patient electronic health records (Epic). All historic testing met ongoing quality control criteria as outlined in the laboratory Quality Management Plan and Individualized Quality Control Plan as required for laboratory accreditation. Subsequently, we performed disc diffusion and D-testing over multiple days using thawed isolates from the freezer bank. After 2 serial propagations on sheep blood agar, we inoculated swabs of 0.5 MacFarland suspensions for confluent growth on cation-adjusted Mueller Hinton agar with 5% sheep blood (BD) using discs containing conventional drug masses. Quality control organisms, including ATCC BAA-977, ATCC BAA-976, and ATCC 49619, were tested in parallel each day of use. We incubated plates at 35C in 5% CO2 environment for 20–24 h before measuring zones of inhibition with a manual caliper in reflected light. We interpreted zone diameters by using CLSI clinical breakpoints (17) and interpreted any degree of clindamycin zone flattening in proximity to erythromycin disc as a positive D-test result.

Susceptibility testing against aminoglycosides (gentamicin, kanamycin, and streptomycin) was performed by agar dilution on Mueller Hinton media (BD) prepared in the research laboratory. A saline suspension of each isolate at an absorbance of 1 Klett unit was prepared and a 10-µL drop (≈104 CFU) was plated in singlicate onto agar medium containing arbitrarily selected concentrations ranging from 50 to 500 μg/mL, as described (5). Plates were incubated at 37°C in 5% CO2 overnight, followed by observation of growth results.



We included 76 GAS isolates collected during January 2020–June 2021 from 66 patients with invasive infections (Figure 1; Appendix Table 1). Median patient age was 42 (mean 45, range 23–86) years; 59% were men. On the basis of addresses listed in medical records, geographic distribution of all 56 in-state patients spanned 20 of the 55 West Virginia counties; 3 northern counties (Harrison, Marion, and Monongalia) accounted for the highest proportion (53%), likely because of larger populations and proximity to the main WVUMed campus in Morgantown. Most out-of-state patients were also within the WVUMed catchment area in neighboring counties in Maryland (n = 4) and Pennsylvania (n = 5) (Figure 1), although 1 patient was visiting from the Midwest United States. For 9 patients, details of housing status in their medical records were insufficient; among the remaining patients, 9 (16%) were reported by a case worker to be experiencing homelessness at the time of culture, despite having an address on file in their medical records. For 64 patients whose social history was sufficiently documented, 39 (61%) reported recent or remote IVDU.

Assessing infection source for all 66 patients collectively revealed 38 (59%) with skin and soft tissue infections (SSTI) of the extremities: 8 (12%) with infections of deep neck structures; 6 (9%) with endovascular sources; 4 (6%) with SSTI of the gluteal, perianal, sacral, or inguinal region; 4 (6%) with respiratory sources; 1 (2%) with ocular source; and 4 (6%) with bloodstream infections of unknown origin (Figure 2). For an additional patient with a history of IVDU who had thrombophlebitis, bacteremia, and multiple SSTIs of the extremities and gluteal region, the primary source could not be discerned. A total of 35 (53%) patients required surgical intervention: single-stage debridement/washout (n = 24), fasciotomy with 2–13 serial debridements (n = 7), below-the-knee amputation revision (n = 1), tricuspid valve replacement (n = 1), thoracotomy with pleural decortication (n=1), and vascular thrombectomy (n = 1) (Appendix Table 1). Of the remaining nonsurgical patients, 8 underwent incision-drainage procedures or chest tube placement at bedside. Overall, 18 (27%) patients required admission to the intensive care unit for >24 hours and at least 5 (7.5%) died as a result of iGAS infection, although records of follow-up care were incomplete for a substantial portion of patients.

Antimicrobial therapy varied considerably by patient acuity, duration of hospitalization, intravenous catheter availability, and degree of initial treatment response. A total of 51 patients (77%) received >1 dose of intravenous vancomycin or daptomycin during hospitalization, whereas β-lactams (amoxicillin/clavulanate, cephems, penicillin, or a combination) or clindamycin were used exclusively for 10 patients (15%). Another 3 patients who were not admitted to the hospital received no antimicrobial therapy. In total, the acuity of infection for 9 patients did not require hospital admission. Another 10 patients left the hospital against medical advice before being admitted or completing treatment, 9 of whom had histories of IVDU. All these patients received prescriptions for oral clindamycin or amoxicillin/clavulanate at discharge. Among the remaining 47 patients, median hospital length of stay was 7 (mean 14, range 1–60) days.

emm Types

Although surveillance across the United States by ABCs has demonstrated an increase in iGAS, categorization of iGAS isolates in West Virginia was lacking. The M protein type of each isolate was determined by Sanger sequencing of the 5′ end of the emm-gene PCR product (Appendix Table 2), as described (16). Analysis showed the collection was predominated by isolates of 1 emm type; of the 66 unique patient isolates, 35 (53.0%) were emm92 followed in decreasing proportion by emm types emm11 (n = 8, 12.1%) and emm89 (n = 5, 7.7%). (Table 1; Figure 3, panel A). Temporal analysis of isolate emm type recovery by 3-month periods showed an overall increase in isolates during April–June in 2020 and 2021; a substantial proportion of the isolates from all quarters were emm type 92. Although the presence of emm11 and emm89 isolates was relatively stable over time, the presence of emm92 trended upward. Of note, the collection contained only 2 emm1 isolates, 1 each of emm12 and emm28, and no emm3 isolates, which historically have been correlated with a high incidence of iGAS infections (Figure 3, panel A) (1,18,19). Although the data from this 1.5-year study period in West Virginia is less robust than ABCs national data, the findings do corroborate a continual shift in emm types responsible for iGAS disease, particularly among homeless populations and persons with a history of IVDU (11,12).

MLSB Susceptibility and Resistance Profiles

Next, we assessed antimicrobial resistance among isolates in our iGAS collection. In aggregate, 76% (50/66) of isolates were resistant to erythromycin (Table 1), which is considerably higher than the percentage reported in a larger collection (11). Aside from emm77, which included 1 erythromycin-resistant isolate and 1 erythromycin-susceptible isolate, all other emm types exclusively harbored either erythromycin-resistant or erythromycin-susceptible phenotypes (Table 1; Figure 3, panel B). We used disc diffusion and D-testing to assess clindamycin susceptibility and to determine whether resistance was constitutive or inducible (Figure 3, panel C). Clindamycin susceptibility mirrored that of erythromycin; 16 erythromycin-susceptible isolates also demonstrated clindamycin susceptibility. Of the 50 erythromycin-resistant isolates, 40 exhibited inducible clindamycin resistance (i.e., not detectable without erythromycin induction), 9 demonstrated constitutive clindamycin resistance, and 1 isolate (emm22) was clindamycin susceptible without evidence of inhibition zone flattening. Similar to erythromycin, most emm types were uniformly susceptible or resistant to clindamycin except for 2 emm77 (1 susceptible and 1 inducible-resistant isolate) (Table 1; Figure 3, panel C). Phenotypic heterogeneity was also noted among emm92 isolates (of which 4 exhibited constitutive clindamycin resistance and 31 exhibited inducible clindamycin resistance), as well as among emm11 isolates (of which 5 isolates produced inducible and 3 produced constitutive phenotypes) (Table 1).

Detection of Erythromycin-Resistance Determinants

We tested isolates for common erythromycin resistance genes by PCR amplification to detect the presence of the methyl transferase genes ermA, ermB, and ermT, as well as mefA, a gene-encoding protein associated with an efflux pump (Appendix Table 2). On the basis of a previous ABCs report that ermT in emm92 GAS was carried on the pRW35 plasmid (15), extrachromosomal DNA was isolated from resistant isolates of various emm types, yet only emm92 isolates harbored plasmid DNA (Figure 4, panel A). Restriction digestion targeting a conserved SwaI site confirmed a ≈4.9-kb size of this pRW35-like plasmid (data not shown). All 35 emm92 isolates were resistant to erythromycin (Table 1) and contained ermT detected by PCR (Figure 4, panel B).

Chromosomal DNA was used for the detection of ermA/B (Figure 4, panels C, D) and mef (data not shown) genes. Erythromycin-resistance genes identified in emm11 isolates varied; 6 carried ermB and 2 harbored ermA (Table 1). Of the remaining 7 erythromycin-resistant isolates of various emm types, ermA was detected in 5, ermB in 1, and mefA in 1. Collectively, 86% of ermA-containing isolates (6 of 7) showed inducible clindamycin resistance, whereas isolates containing ermB had a more evenly split phenotype for clindamycin resistance (3 iMLSB vs. 4 cMLSB) (Table 1). The mefA gene, which encodes a component of the mefA-msrD efflux pump, was detected in a single emm22 isolate and corresponded to the erythromycin-resistant, clindamycin-susceptible phenotype referred to as the M phenotype (20).

Additional Susceptibility and Proposed Resistance Determinants

Isolates also underwent susceptibility testing for tetracycline by disc diffusion, as well as for the aminoglycosides (gentamicin, streptomycin, and kanamycin) by agar dilution method using concentration ranges as previously described (5). In aggregate, 76% of isolates were resistant to both tetracycline and erythromycin, whereas the single emm87 isolate was erythromycin sensitive but tetracycline resistant. For aminoglycosides, all 66 isolates were susceptible to gentamicin using CLSI Staphylococcus aureus breakpoints, whereas we observed presumed resistance to kanamycin (MIC >500 µg/mL) in 89% of tested isolates and resistance to streptomycin (MIC >500 µg/mL) in 61% of isolates. In addition to their universal plasmid-encoded MLSB phenotype, all emm92 strains in this collection were uniformly resistant to tetracycline, kanamycin, and streptomycin, presumably encoded by the ICESpyM92 mobile element (Table 2) (5). The remaining isolates of various emm types with MLSB phenotype demonstrated resistance to either kanamycin or tetracycline.


This study represents a comprehensive characterization of iGAS isolates from West Virginia, a geographic area beyond ABC surveillance, on the basis of the relationship between emm type and macrolide resistance. The results confirm a very high rate of erythromycin resistance (76%) across 7 different emm types producing invasive infections, most of which displayed MLSB phenotype and were concomitantly resistant to clindamycin. A relationship between emm type and erythromycin-resistance mechanisms in this collection also became apparent. We observed that type emm92 represented 53% of patient isolates and emm11 12% of patient isolates, but together those types accounted for 86% of erythromycin-resistant strains. The third most prevalent emm type was emm89, although all isolates were susceptible to erythromycin. These findings corroborate 2010–2019 nationwide data from ABCs, which demonstrated an increasing incidence of iGAS infections caused by emm92, emm11, and emm89 types affecting the adult US population (11,2224). By contrast, emm92 iGAS infections have been reported only sporadically and at much lower frequencies globally (25,26), suggesting that expansion and dissemination of this organism might thus far be limited to the United States. Nonetheless, all 3 emm types are represented in the 30-valent M protein–based vaccine, signifying their role in GAS disease (27).

All emm92 strains in this study harbored the pRW35-like plasmid containing the ermT gene, which confers resistance to erythromycin. Plasmids harboring the conserved ermT gene have been found in several medically relevant bacteria, including S. pyogenes, S. agalactiae, methicillin-resistant strains of Staphylococcus aureus, S. gallolyticus subspecies pasteurianus, and S. suis, which suggests horizontal gene transfer (15,2830). The practice of using animal feed containing tylosin, a macrolide additive, has been suggested as a contributing factor in the spread of ermT across different species (30). The second most commonly identified emm type was emm11, in which resistance was enabled by either the ermA or ermB gene. In contrast to emm92, infections caused by the emm11 strains displaying MLSB phenotype have been broadly reported around the world (4,3134), including fluoroquinolone-resistant isolates in China (35). We observed 5 iGAS infections related to emm89. Acapsular emm89 strains emerged as a key cause of iGAS infections worldwide (34,3638). Those strains also contain a mutation in the nga promoter leading to higher expression of cytotoxins NADase and streptolysin O (36,39).

We also tested resistance to tetracycline, kanamycin, streptomycin, and gentamicin. No strains were resistant to gentamicin, but all emm92 strains demonstrated resistance to kanamycin, streptomycin, and tetracycline. Sanson et al. (5) used whole-genome sequencing to demonstrate that emm92 isolates contain the ICESpyM92 element carrying the tet(M), ant (6)-Ia, and aph-(3′)-III genes, which accounts for resistance to tetracycline and the 2 aminoglycosides (also observed in this study) and has subsequently been linked to increased virulence of emm92 strains (40). Further, that research showed that emm11 isolates harboring ermB and exhibiting resistance to tetracycline and kanamycin contained a Tn6003-like transposon carrying the aph (3′)-III gene, whereas those harboring ermB and tetracycline resistance alone carried Tn6002 (5). All 6 emm11 isolates with ermB from this study displayed 1 of these 2 phenotypes. Other studies have reported ICESp2905 as the cause of resistance to tetracycline, erythromycin, and kanamycin in emm11 isolates containing the ermA gene (21,41), which reflects the phenotypic pattern of 2 such isolates observed in this collection. Our collection contained 1 emm22 isolate displaying M phenotype encoded by mefA, which could be carried on the transposon Tn1207.3 (5,42). Overall, these results suggest that many iGAS strains in West Virginia, especially emm92 strains, are resistant to multiple classes of antimicrobial drugs, in addition to macrolides.

This study corroborates earlier reports noting the emergence of macrolide-resistant emm92 iGAS nationally (5,11,22,4345). We observed emm92 as the predominant M type in every quarter, although an overall decrease in incidence was noted during July–September 2020. Quarantine related to the COVID-19 pandemic might in part explain this decrease, although periodic seasonality in disease incidence might also be a contributing factor. Nationwide data from 2010–2017 identified emm92, emm49, and emm82 as predominant iGAS types among patients with a history of IVDU and in those experiencing homelessness (22), but 2020–2021 West Virginia data identified emm92, emm11, and emm89 as the top 3 iGAS types. In addition, CDC surveillance detected considerable numbers of historically classical iGAS emm types (e.g., emm1, emm12, emm28, and emm3), whereas our collection did not. Our results signify an area deserving of future investigation because of the emerging dominance of the emm92 type in iGAS infections across the United States.

Drug abuse has become a serious epidemic in West Virginia; rates of overdose deaths have risen starting in 1999 (46). Patient data from this cohort corroborate that IVDU is a risk factor for resistant iGAS infections; 60.6% of affected patients reported IVDU, compared with 8.7% reported by the ABCs program. Recent studies have documented increases in drug use and overdose indicators during the COVID-19 pandemic, including higher rates of emergency department visits, emergency medical service dispatches, urine drug screen positivity, and death (47,48). Similarly, a study from Ontario, Canada, focusing on IVDU noted a 2-fold higher rate of IVDU-related SSTI than for the prepandemic era (49). At J.W. Ruby Memorial Hospital, overall GAS isolate recovery (calculated as total unique patient isolates per total aerobic cultures performed) declined during the pandemic, decreasing from 0.83% (890/107,150) in 2018–2019 to 0.54% (520/96,380) in 2020–2021, yet the percentage, rate, and absolute number of iGAS isolates among these totals increased substantially, from 159/892 (18%) isolates in 2018–2019 to 252/518 (49%) isolates in 2020–2021. Whether or to what extent increased IVDU during our study period affected strain diversity or resistance rates is unknown.

Homelessness among persons in West Virginia is also increasing. As of January 2020, an estimated 1,341 persons in the state experienced homelessness on any given day (50). In our study cohort, homelessness was reported by 13.6% of patients who had adequate documentation; 88.8% of those had a history of IVDU. In comparison, a study encompassing the 10 nationwide ABCs sites during 2010–2017 reported homelessness in 5.8% of patients and both risk factors in 6.1% of persons (22).

The first limitation of our study is that, although this collection of iGAS isolates was derived from a broad geographic area of the state, it did not include all invasive strains for the periods represented. Much of southern West Virginia is beyond the WVUMed catchment area, and isolates from some WVUMed hospitals and other health systems would not have been captured. Further, because our hospital laboratory only banks invasive strains, we were unable to compare genotypic or phenotypic features of pharyngitis strains. Resistance determinants for tetracycline and aminoglycosides were not defined here. We also did not explore reasons for variable inducible/constitutive phenotype within emm types harboring same erm determinant, although research is ongoing.

In conclusion, we describe the clinicoepidemiology of iGAS infections in West Virginia over a 1.5-year period, identifying prevalent emm types and associated patient risk factors. Our findings indicate a particular vulnerability to iGAS infections associated with socioeconomic status, which clearly affected this study population (46). Further studies of emm92 iGAS isolates and categorization of resistance will be key to improve treatments and guidelines for preventing resistance. Providing greater information and access to supplies for preventing iGAS infections in those most at risk might help reduce the spread of resistant iGAS strains in the United States.



We thank the Centers for Disease Control and Prevention Emerging Infection Program laboratory for providing control group A Streptococcus strains.

S.L. and M.E.G. acknowledge funding from a grant awarded as a result of Broad Agency Announcement (BAA) HDTRA1-14-24-FRCWMD-Research and Development Enterprise, Basic and Applied Sciences Directorate, Basic Research for Combating Weapons of Mass Destruction (C-WMD), under contract #HDTRA1035955001, and in part by the Vaccine Development center at WVU-HSC, Research Challenge Grant no.HEPC.dsr.18.6 from the Division of Science and Research, WV Higher Education Policy Commission, and by the Transition Grant Support; Office of Research and Graduate Education, WVU Health Sciences Center (to S.L.). L.M.P. and C.E.C. were supported by the Department of Microbiology, Immunology and Cell Biology Research Internship for Undergraduates in the Immunology and Medical Microbiology degree program.



  1. Stevens  DL. Invasive group A streptococcus infections. Clin Infect Dis. 1992;14:211. DOIPubMedGoogle Scholar
  2. Carapetis  JR, Beaton  A, Cunningham  MW, Guilherme  L, Karthikeyan  G, Mayosi  BM, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084. DOIPubMedGoogle Scholar
  3. Walker  MJ, Barnett  TC, McArthur  JD, Cole  JN, Gillen  CM, Henningham  A, et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin Microbiol Rev. 2014;27:264301. DOIPubMedGoogle Scholar
  4. Silva-Costa  C, Friães  A, Ramirez  M, Melo-Cristino  J. Macrolide-resistant Streptococcus pyogenes: prevalence and treatment strategies. Expert Rev Anti Infect Ther. 2015;13:61528. DOIPubMedGoogle Scholar
  5. Sanson  MA, Macias  OR, Shah  BJ, Hanson  B, Vega  LA, Alamarat  Z, et al. Unexpected relationships between frequency of antimicrobial resistance, disease phenotype and emm type in group A Streptococcus. Microb Genom. 2019;5:e000316. DOIPubMedGoogle Scholar
  6. Mingoia  M, Morici  E, Morroni  G, Giovanetti  E, Del Grosso  M, Pantosti  A, et al. Tn5253 family integrative and conjugative elements carrying mef(I) and catQ determinants in Streptococcus pneumoniae and Streptococcus pyogenes. Antimicrob Agents Chemother. 2014;58:588693. DOIPubMedGoogle Scholar
  7. Berbel  D, Càmara  J, García  E, Tubau  F, Guérin  F, Giard  JC, et al. A novel genomic island harbouring lsa(E) and lnu(B) genes and a defective prophage in a Streptococcus pyogenes isolate resistant to lincosamide, streptogramin A and pleuromutilin antibiotics. Int J Antimicrob Agents. 2019;54:64751. DOIPubMedGoogle Scholar
  8. Centers for Disease Control and Prevention. Erythromycin-resistant group A Streptococcus [cited 2021 Nov 23].
  9. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs): Emerging Infections Program network, group A Streptococcus, 2010 [cited 2012 Jan 5].
  10. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report: Emerging Infections Program network, group A Streptococcus, 2019 [cited 2022 Jun 16].
  11. Fay  K, Onukwube  J, Chochua  S, Schaffner  W, Cieslak  P, Lynfield  R, et al. Patterns of antibiotic nonsusceptibility among invasive group A Streptococcus infections—United States, 2006–2017. Clin Infect Dis. 2021;73:195764. DOIPubMedGoogle Scholar
  12. Bruun  T, Rath  E, Madsen  MB, Oppegaard  O, Nekludov  M, Arnell  P, et al.; INFECT Study Group. Risk factors and predictors of mortality in streptococcal necrotizing soft-tissue infections: a multicenter prospective study. Clin Infect Dis. 2021;72:293300. DOIPubMedGoogle Scholar
  13. Centers for Disease Control and Prevention. 2020 drug overdose death rates [cited 2022 Jul 27].
  14. Goldenberger  D, Perschil  I, Ritzler  M, Altwegg  M. A simple “universal” DNA extraction procedure using SDS and proteinase K is compatible with direct PCR amplification. PCR Methods Appl. 1995;4:36870. DOIPubMedGoogle Scholar
  15. Woodbury  RL, Klammer  KA, Xiong  Y, Bailiff  T, Glennen  A, Bartkus  JM, et al.; Active Bacterial Core Surveillance Team. Plasmid-Borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains. Antimicrob Agents Chemother. 2008;52:11403. DOIPubMedGoogle Scholar
  16. Beall  B, Facklam  R, Thompson  T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol. 1996;34:9538. DOIPubMedGoogle Scholar
  17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 31st ed. CLSI supplement M100. Wayne (PA): The Institute; 2021.
  18. Musser  JM, Hauser  AR, Kim  MH, Schlievert  PM, Nelson  K, Selander  RK. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A. 1991;88:266872. DOIPubMedGoogle Scholar
  19. Jain  I, Sarkar  P, Danger  JL, Medicielo  J, Roshika  R, Calfee  G, et al. A mobile genetic element promotes the association between serotype M28 group A Streptococcus isolates and cases of puerperal sepsis. J Infect Dis. 2019;220:88291. DOIPubMedGoogle Scholar
  20. Blackman Northwood  J, Del Grosso  M, Cossins  LR, Coley  MD, Creti  R, Pantosti  A, et al. Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. Antimicrob Agents Chemother. 2009;53:19215. DOIPubMedGoogle Scholar
  21. Giovanetti  E, Brenciani  A, Lupidi  R, Roberts  MC, Varaldo  PE. Presence of the tet(O) gene in erythromycin- and tetracycline-resistant strains of Streptococcus pyogenes and linkage with either the mef(A) or the erm(A) gene. Antimicrob Agents Chemother. 2003;47:28449. DOIPubMedGoogle Scholar
  22. Valenciano  SJ, Onukwube  J, Spiller  MW, Thomas  A, Como-Sabetti  K, Schaffner  W, et al. Invasive group A streptococcal infections among people who inject drugs and people experiencing homelessness in the United States, 2010–2017. Clin Infect Dis. 2021;73:e371826. DOIPubMedGoogle Scholar
  23. Chochua  S, Metcalf  BJ, Li  Z, Rivers  J, Mathis  S, Jackson  D, et al. Population and whole genome sequence based characterization of invasive group A streptococci recovered in the United States during 2015. MBio. 2017;8:e0142217. DOIPubMedGoogle Scholar
  24. Li  Y, Rivers  J, Mathis  S, Li  Z, Velusamy  S, Nanduri  SA, et al. Genomic surveillance of Streptococcus pyogenes strains causing invasive disease, United States, 2016–2017. Front Microbiol. 2020;11:1547. DOIPubMedGoogle Scholar
  25. Le Hello  S, Doloy  A, Baumann  F, Roques  N, Coudene  P, Rouchon  B, et al. Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia, a region in Oceania with a high incidence of acute rheumatic fever. [Erratum in: J Clin Microbiol. 2010;48:1993]. J Clin Microbiol. 2010;48:52630. DOIPubMedGoogle Scholar
  26. Abraham  T, Sistla  S. Molecular epidemiology of macrolide resistant Group A streptococci from Puducherry, India. J Infect Dev Ctries. 2017;11:67983. DOIPubMedGoogle Scholar
  27. Dale  JB, Penfound  TA, Chiang  EY, Walton  WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine. 2011;29:81758. DOIPubMedGoogle Scholar
  28. Palmieri  C, Magi  G, Creti  R, Baldassarri  L, Imperi  M, Gherardi  G, et al. Interspecies mobilization of an ermT-carrying plasmid of Streptococcus dysgalactiae subsp. equisimilis by a coresident ICE of the ICESa2603 family. J Antimicrob Chemother. 2013;68:236. DOIPubMedGoogle Scholar
  29. Kadlec  K, Schwarz  S. Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain. Antimicrob Agents Chemother. 2010;54:9158. DOIPubMedGoogle Scholar
  30. DiPersio  LP, DiPersio  JR, Beach  JA, Loudon  AM, Fuchs  AM. Identification and characterization of plasmid-borne erm(T) macrolide resistance in group B and group A Streptococcus. Diagn Microbiol Infect Dis. 2011;71:21723. DOIPubMedGoogle Scholar
  31. Ksia  S, Smaoui  H, Hraoui  M, Bouafsoun  A, Boutiba-Ben Boubaker  I, Kechrid  A. Molecular characteristics of erythromycin-resistant Streptococcus pyogenes strains isolated from children patients in Tunis, Tunisia. Microb Drug Resist. 2017;23:6339. DOIPubMedGoogle Scholar
  32. Bocking  N, Matsumoto  CL, Loewen  K, Teatero  S, Marchand-Austin  A, Gordon  J, et al. High incidence of invasive group A streptococcal infections in remote indigenous communities in Northwestern Ontario, Canada. Open Forum Infect Dis. 2016;4:ofw243. DOIPubMedGoogle Scholar
  33. Meehan  M, Murchan  S, Gavin  PJ, Drew  RJ, Cunney  R. Epidemiology of an upsurge of invasive group A streptococcal infections in Ireland, 2012-2015. J Infect. 2018;77:18390. DOIPubMedGoogle Scholar
  34. Hasegawa  T, Hata  N, Matsui  H, Isaka  M, Tatsuno  I. Characterisation of clinically isolated Streptococcus pyogenes from balanoposthitis patients, with special emphasis on emm89 isolates. J Med Microbiol. 2017;66:5116. DOIPubMedGoogle Scholar
  35. Shen  Y, Cai  J, Davies  MR, Zhang  C, Gao  K, Qiao  D, et al. Identification and characterization of fluoroquinolone non-susceptible Streptococcus pyogenes clones harboring tetracycline and macrolide resistance in Shanghai, China. Front Microbiol. 2018;9:542. DOIPubMedGoogle Scholar
  36. Zhu  L, Olsen  RJ, Nasser  W, de la Riva Morales  I, Musser  JM. Trading capsule for increased cytotoxin production: contribution to virulence of a newly emerged clade of emm89 Streptococcus pyogenes. MBio. 2015;6:e0137815. DOIPubMedGoogle Scholar
  37. Turner  CE, Abbott  J, Lamagni  T, Holden  MT, David  S, Jones  MD, et al. Emergence of a new highly successful acapsular group A Streptococcus clade of genotype emm89 in the United Kingdom. MBio. 2015;6:e00622. DOIPubMedGoogle Scholar
  38. Wajima  T, Chiba  N, Morozumi  M, Shouji  M, Sunaoshi  K, Sugita  K, et al.; GAS Surveillance Study Group. Prevalence of macrolide resistance among group A streptococci isolated from pharyngotonsillitis. Microb Drug Resist. 2014;20:4315. DOIPubMedGoogle Scholar
  39. Turner  CE, Holden  MTG, Blane  B, Horner  C, Peacock  SJ, Sriskandan  S. The emergence of successful Streptococcus pyogenes lineages through convergent pathways of capsule loss and recombination directing high toxin expression. MBio. 2019;10:e0252119. DOIPubMedGoogle Scholar
  40. Vega  LA, Sanson  MA, Cubria  MB, Regmi  S, Shah  BJ, Shelburne  SA, et al. The integrative conjugative element ICESpyM92 contributes to pathogenicity of emergent antimicrobial-resistant emm92 group A Streptococcus. Infect Immun. 2022;90:e0008022. DOIPubMedGoogle Scholar
  41. Partridge  SR, Kwong  SM, Firth  N, Jensen  SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018;31:e0008817. DOIPubMedGoogle Scholar
  42. Chancey  ST, Bai  X, Kumar  N, Drabek  EF, Daugherty  SC, Colon  T, et al. Transcriptional attenuation controls macrolide inducible efflux and resistance in Streptococcus pneumoniae and in other Gram-positive bacteria containing mef/mel(msr(D)) elements. PLoS One. 2015;10:e0116254. DOIPubMedGoogle Scholar
  43. Metcalf  B, Nanduri  S, Chochua  S, Li  Y, Fleming-Dutra  K, McGee  L, et al. Cluster transmission drives invasive group A Streptococcus disease within the United States and is focused on communities experiencing disadvantage. J Infect Dis. 2022;226:54653. DOIPubMedGoogle Scholar
  44. Li  Y, Rivers  J, Mathis  S, Li  Z, McGee  L, Chochua  S, et al. Continued increase of erythromycin- and clindamycin-nonsusceptibility among invasive group A streptococci driven by genomic clusters, USA, 2018–2019. Clin Infect Dis. 2022.
  45. Chochua  S, Metcalf  B, Li  Z, Mathis  S, Tran  T, Rivers  J, et al. Invasive group A streptococcal penicillin binding protein 2× variants associated with reduced susceptibility to β-lactam antibiotics in the United States, 2015–2021. Antimicrob Agents Chemother. 2022;66:e0080222. DOIPubMedGoogle Scholar
  46. National Institute on Drug Abuse. West Virginia: opioid-involved deaths and related harms. 2020 [cited 2022 May 5].
  47. Imtiaz  S, Nafeh  F, Russell  C, Ali  F, Elton-Marshall  T, Rehm  J. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. Subst Abuse Treat Prev Policy. 2021;16:87. DOIPubMedGoogle Scholar
  48. Simha  S, Ahmed  Y, Brummett  CM, Waljee  JF, Englesbe  MJ, Bicket  MC. Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: a systematic review. Reg Anesth Pain Med. 2023;48:3743. DOIPubMedGoogle Scholar
  49. McRae  M, Sardiwalla  Y, Nachmani  O, Price  E, Huynh  M, Coroneos  C. Upper extremity infection related to intravenous drug use: considering the true cost of the COVID-19 pandemic and lockdown. Hand (N Y). 2022;15589447221077377; Epub ahead of print. DOIPubMedGoogle Scholar
  50. United States Interagency Council on Homelessness. West Virginia homelessness statistics. 2020 [cited 2022 May 5].




Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on If you are not registered on, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, For technical assistance, contact American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title: 
Emergence of Erythromycin-Resistant Invasive Group A Streptococcus, West Virginia, USA, 2020–2021
CME Questions
  • Your patient is a 37-year-old man with a history of intravenous drug use (IVDU) who was just diagnosed with invasive group A Streptococcus pyogenes (iGAS) infection. On the basis of the study at J.W. Ruby Memorial Hospital in West Virginia from 2020 to 2021 by Powell and colleagues, which one of the following statements about the clinicoepidemiology of iGAS infections is correct?

    • Most patients were elderly

    • More than half of patients were experiencing homelessness at the time of culture; 20% had recent or remote IVDU

    • The most common infection source was respiratory

    • Antimicrobial therapy varied considerably by patient acuity, length of hospitalization, IV catheter availability, and initial treatment response

  • According to the study at J.W. Ruby Memorial Hospital in West Virginia from 2020 to 2021 by Powell and colleagues, which one of the following statements about the specific phenotypic and genotypic antimicrobial resistance traits of available isolates from iGAS infections is correct?

    • 76% of isolates were simultaneously resistant to erythromycin and clindamycin

    • Susceptible isolates were primarily emm11

    • All emm92 and emm89 isolates were simultaneously resistant to erythromycin and clindamycin

    • Macrolide-resistant isolates were typically sensitive to tetracycline and aminoglycosides

  • On the basis of the study at J.W. Ruby Memorial Hospital in West Virginia from 2020 to 2021 by Powell and colleagues, which one of the following statements about clinical and public health implications of the clinicoepidemiology of iGAS infections and specific phenotypic and genotypic antimicrobial resistance traits of corresponding available isolates is correct?

    • The study findings do not corroborate Active Bacterial Core (ABC)-Centers for Disease Control and Prevention (CDC) national data

    • Predominance of erythromycin resistance and emm92 suggest increased emergence of resistance and clonal dissemination

    • Across all populations, emm-type distribution remained stable compared with historical reports

    • The findings do not suggest predisposition to iGAS infections based on socioeconomic status


Cite This Article

DOI: 10.3201/eid2905.221421

Original Publication Date: April 14, 2023

1These senior authors contributed equally to this article.

Related Links

Table of Contents – Volume 29, Number 5—May 2023

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Slawomir Lukomski, West Virginia University, 2095 Health Sciences North, Morgantown, WV 26506, USA

Send To

10000 character(s) remaining.


Page created: March 06, 2023
Page updated: April 14, 2023
Page reviewed: April 14, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.